Cockcroft-Gault Equation for Estimating Creatinine Clearance

Table of Contents

The 1976 Cockcroft-Gault (C-G) estimated creatinine clearance (eCrCL) equation has been used for almost 50 years to inform medication dosing for people with impaired kidney disease filtration function. However, the healthcare environment has changed significantly since this equation was originally developed. As such, the National Kidney Foundation advocates transitioning away from using C-G eCrCL and towards the race-agnostic estimated glomerular filtration rate (eGFR) equations (adjusted for body surface area) for medication-related decision-making in adults. A brief overview of the rationale for this recommendation is provided below.

Limitations of the Cockcroft-Gault equation

The C-G eCrCL equation was:

  • Developed with data from 249 white males, with the 15% adjustment for females estimated rather than scientifically quantified.1 It has not been validated for use in large, more diverse patient populations compared to recommended eGFR equations.
  • Developed in an era when serum creatinine (Scr) assays were not standardized. By 2011, the majority of Scr assay methods had been standardized to an isotope dilution mass spectrometry (IDMS) reference measurement procedure.2 In short, the average Scr value has decreased by 12%.3 Consequently, C-G eCrCL values today are higher than values obtained during pharmacokinetic studies used to create dosing recommendations before 2011.
  • Validated against measured creatinine clearance (mCrCL), which is known to overestimate GFR, while contemporary eGFR equations were validated against measured GFR (mGFR), the current standard for assessing kidney filtration.

Limitations of Practice Adaptations to C-G eCrCL

  • As the average body weight of the US population has increased, use of total body weight (or any single body weight parameter) across the body size or weight spectrum reduces C-G eCrCL accuracy.4,5 Furthermore, body weight parameters are inconsistently applied across clinicians, institutions, and practice settings, leading to significant variability in results and interpretation.6
  • Adaptations for older age are also commonly used by many pharmacists and embedded in some electronic health record (EHR) calculators. These usually include inflating a patient’s Scr empirically when it is lower than the normal range through the use of highly variable criteria, though there is clear evidence to refute this empiric adjustment.4,7 This Scr adjustment further contributes to the variability observed in C-G eCrCL results across the US.

Recent Developments Driving the Need for Change

  • Pharmaceutical companies are increasingly using eGFR in pharmacokinetic studies, with a resultant increase in eGFR-based dosing recommendations.8 The US Food and Drug Administration 2024 final guidance for industry recommends the "use of eGFR to determine renal function in pharmacokinetic (PK) studies… over eCLcr [eCrCL]".9
  • While C-G eCrCL is easier to calculate manually than eGFR, the widespread adoption of EHR systems and ubiquitous automatic reporting of eGFR concurrently with Scr has negated this potential advantage.

Applying eGFR to Medication-Related Decision-Making

The National Kidney Foundation Workgroup for Implementation of Race-Agnostic eGFR-Based Medication-Related Decisions recommends transitioning from C-G eCrCL to the race-agnostic eGFR equations for medication-related decision-making in adults, emphasizing the following principles:

  • Race should not be used in the calculation of eGFR.10–13 The race-agnostic equations for estimating eGFR recommended by the ASN/NKF Task Force include the 2021 CKD-EPIcr, 2021 CKD-EPIcr-cys, and 2012 CKD-EPIcys equations. The MDRD, 2009 CKD-EPIcr, and 2012 CKD-EPIcr-cys equations include an adjustment for African American race and therefore should not be used.
  • eGFR results should be adjusted for individuals' BSA for medication dosing.12,13 In order to compare and trend GFR across patient populations, eGFR equations were standardized to a BSA of 1.73 m2 and reported in units of mL/min/1.73 m2. However, medication dosing should be based on the patient's individualized kidney function, which aligns with body size. Therefore, the standardized eGFR (mL/min/1.73m2) should be adjusted for the patient's BSA (eGFRBSAadj) when used for medication dosing. This can be done by dividing the reported eGFR value by 1.73m2 and multiplying by the patient's BSA, resulting in mL/min (or using the NKF eGFR calculator).

The Workgroup offers guidance to assist in this transformation, Moving Forward from Cockcroft and Gault Creatinine Clearance to Race-Free Estimated Glomerular Filtration Rate to Improve Medication-Related Decision-Making in Adults Across Healthcare Settings: A Consensus of the National Kidney Foundation Workgroup for Implementation of Race-Free eGFR-Based Medication-Related Decisions, published in the American Journal of Health-System Pharmacy.

References

  1. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41. doi:10.1159/000180580
  2. Killeen AA, Ashwood ER, Ventura CB, Styer P. Recent trends in performance and current state of creatinine assays. Arch Pathol Lab Med. 2013;137(4):496-502. doi:10.5858/arpa.2012-0134-CP
  3. Piéroni L, Delanaye P, Boutten A, et al. A multicentric evaluation of IDMS-traceable creatinine enzymatic assays. Clin Chim Acta. 2011;412(23-24):2070-2075. doi:10.1016/j.cca.2011.07.012
  4. Winter MA, Guhr KN, Berg GM. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation. Pharmacotherapy. 2012;32(7):604-612. doi:10.1002/j.1875-9114.2012.01098.x
  5. Pai MP. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy. 2012;32(9):856-868. doi:10.1002/j.1875-9114.2012.01108.x
  6. Nemecek BD, St. Peter WL, Hong LT, Anderson ER, El Nekidy WS. Current Practices in Estimating Kidney Function: Insights From a Cross‐Sectional Survey. J Am Coll Clin Pharm. 2025;8(11):1136-1142. doi:10.1002/jac5.70123
  7. Dowling TC, Wang ES, Ferrucci L, Sorkin JD. Glomerular filtration rate equations overestimate creatinine clearance in older individuals enrolled in the Baltimore Longitudinal Study on Aging: impact on renal drug dosing. Pharmacotherapy. 2013;33(9):912-921. doi:10.1002/phar.1282
  8. Crass RL, Pai MP. Estimating renal function in drug development: time to take the fork in the road. J Clin Pharmacol. 2019;59(2):159-167. doi:10.1002/jcph.1314
  9. United States Food & Drug Administration Center for Drug Evaluation and Research (CDER). Pharmacokinetics in patients with impaired renal function — study design, data analysis, and impact on dosing (guidance for industry). Published online March 15, 2024. Accessed February 4, 2025. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacokinetics-patients-impaired-renal-function-study-design-data-analysis-and-impact-dosing
  10. Delgado C, Baweja M, Crews DC, et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. Am J Kidney Dis. 2022;79(2):268-288.e1. doi:10.1053/j.ajkd.2021.08.003
  11. Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737-1749. doi:10.1056/NEJMoa2102953
  12. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018
  13. Navaneethan SD, Bansal N, Cavanaugh KL, et al. KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD. American Journal of Kidney Diseases. 2025;85(2):135-176. doi:10.1053/j.ajkd.2024.08.003